Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Opiant and Titan to develop product for opioid use disorder

Oct. 3, 2017

NIDA grant supports Camino Pharma's development of compounds for substance use disorders

Sep. 29, 2017

Aeolus Pharmaceuticals' AEOL-10150 safe and well-tolerated in phase I study

Sep. 20, 2017

Emergent Biosolutions awarded funding to develop antidote spray for cyanide poisoning

Sep. 20, 2017

FDA accepts Camurus' NDA for CAM-2038 buprenorphine depots

Sep. 19, 2017

FDA grants priority review to Braeburn's NDA for CAM-2038 for opioid use disorder

Sep. 18, 2017

CHMP adopts positive opinion for Zubsolv as treatment of opioid dependence

Sep. 18, 2017

Ophirex licenses sPLA2 inhibitor data from Lilly and Shionogi to support snakebite program

Aug. 29, 2017

Pluristem starts pilot study to test PLX-R18 cell therapy for acute radiation syndrome

Aug. 17, 2017

Soligenix receives additional NIAID funding for the development of heat stable ricin vaccine

Aug. 16, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...